BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36952395)

  • 1. Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors.
    Liu S; Abboud M; Mikhailov V; Liu X; Reinbold R; Schofield CJ
    J Med Chem; 2023 Apr; 66(7):5279-5288. PubMed ID: 36952395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural and synthetic 2-oxoglutarate derivatives are substrates for oncogenic variants of human isocitrate dehydrogenase 1 and 2.
    Liu X; Reinbold R; Liu S; Herold RA; Rabe P; Duclos S; Yadav RB; Abboud MI; Thieffine S; Armstrong FA; Brewitz L; Schofield CJ
    J Biol Chem; 2023 Feb; 299(2):102873. PubMed ID: 36621625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1.
    Liu S; Abboud MI; John T; Mikhailov V; Hvinden I; Walsby-Tickle J; Liu X; Pettinati I; Cadoux-Hudson T; McCullagh JSO; Schofield CJ
    Commun Biol; 2021 Nov; 4(1):1243. PubMed ID: 34725432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
    Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
    Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
    Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
    Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
    Sesanto R; Kuehn JF; Barber DL; White KA
    Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
    Liu S; Cadoux-Hudson T; Schofield CJ
    Curr Opin Chem Biol; 2020 Aug; 57():122-134. PubMed ID: 32777735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting Electrode Nanoconfinement to Investigate the Catalytic Properties of Isocitrate Dehydrogenase (IDH1) and a Cancer-Associated Variant.
    Herold RA; Reinbold R; Megarity CF; Abboud MI; Schofield CJ; Armstrong FA
    J Phys Chem Lett; 2021 Jul; 12(26):6095-6101. PubMed ID: 34170697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational study on novel natural compound inhibitor targeting IDH1_R132H.
    Zhou B; Yang F; Qin L; Kuai J; Yang L; Zhang L; Sun P; Li G; Wang X
    Aging (Albany NY); 2022 Jul; 14(13):5478-5492. PubMed ID: 35802554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
    Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
    J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrochemical Nanoreactor Provides a Comprehensive View of Isocitrate Dehydrogenase Cancer-drug Kinetics.
    Herold RA; Schofield CJ; Armstrong FA
    Angew Chem Int Ed Engl; 2023 Oct; 62(42):e202309149. PubMed ID: 37607127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
    Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
    J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
    Chambers JM; Miller W; Quichocho G; Upadhye V; Matteo DA; Bobkov AA; Sohl CD; Schiffer JM
    Biochemistry; 2020 Feb; 59(4):479-490. PubMed ID: 31869219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration.
    Kang S; Kwon HN; Kang S; Park S
    Biochem Biophys Res Commun; 2020 Mar; 524(1):224-230. PubMed ID: 31983428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.
    Yang B; Zhong C; Peng Y; Lai Z; Ding J
    Cell Res; 2010 Nov; 20(11):1188-200. PubMed ID: 20975740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.